WO2006015263A3 - Analogues de lonidamine - Google Patents

Analogues de lonidamine Download PDF

Info

Publication number
WO2006015263A3
WO2006015263A3 PCT/US2005/027092 US2005027092W WO2006015263A3 WO 2006015263 A3 WO2006015263 A3 WO 2006015263A3 US 2005027092 W US2005027092 W US 2005027092W WO 2006015263 A3 WO2006015263 A3 WO 2006015263A3
Authority
WO
WIPO (PCT)
Prior art keywords
lonidamine analogs
lonidamine
analogs
bph
cancer
Prior art date
Application number
PCT/US2005/027092
Other languages
English (en)
Other versions
WO2006015263A2 (fr
Inventor
Mark Matteucci
Photon Rao
Jian-Xin Duan
Original Assignee
Threshold Pharmaceuticals Inc
Mark Matteucci
Photon Rao
Jian-Xin Duan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc, Mark Matteucci, Photon Rao, Jian-Xin Duan filed Critical Threshold Pharmaceuticals Inc
Priority to US11/346,632 priority Critical patent/US20070043057A1/en
Priority to US11/351,347 priority patent/US20070015771A1/en
Publication of WO2006015263A2 publication Critical patent/WO2006015263A2/fr
Publication of WO2006015263A3 publication Critical patent/WO2006015263A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention a trait à des analogues de lonidamine utiles dans le traitement du cancer et de l'hypertrophie bénigne de la prostate.
PCT/US2005/027092 2004-07-29 2005-07-29 Analogues de lonidamine WO2006015263A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/346,632 US20070043057A1 (en) 2005-02-09 2006-02-01 Lonidamine analogs
US11/351,347 US20070015771A1 (en) 2004-07-29 2006-02-08 Lonidamine analogs

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US59272304P 2004-07-29 2004-07-29
US59283304P 2004-07-29 2004-07-29
US60/592,723 2004-07-29
US60/592,833 2004-07-29
US59966604P 2004-08-05 2004-08-05
US60/599,666 2004-08-05
US64618805P 2005-01-21 2005-01-21
US60/646,188 2005-01-21
US65170505P 2005-02-09 2005-02-09
US60/651,705 2005-02-09
US66106705P 2005-03-11 2005-03-11
US60/661,067 2005-03-11
US68308705P 2005-05-19 2005-05-19
US60/683,087 2005-05-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/346,632 Continuation-In-Part US20070043057A1 (en) 2004-07-29 2006-02-01 Lonidamine analogs

Publications (2)

Publication Number Publication Date
WO2006015263A2 WO2006015263A2 (fr) 2006-02-09
WO2006015263A3 true WO2006015263A3 (fr) 2006-07-27

Family

ID=35787877

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/027092 WO2006015263A2 (fr) 2004-07-29 2005-07-29 Analogues de lonidamine

Country Status (2)

Country Link
TW (1) TW200612918A (fr)
WO (1) WO2006015263A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
MX2007012082A (es) 2005-03-31 2007-11-20 Pfizer Prod Inc Derivados de ciclopentapiridina y tetrahidroquinolina.
JP5180824B2 (ja) 2005-06-29 2013-04-10 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド ホスホルアミデートアルキル化剤プロドラッグ
ES2374455T3 (es) 2006-02-17 2012-02-16 Pfizer Limited Derivados de 3-deazapurinza como moduladores de tlr7.
US7501438B2 (en) 2006-07-07 2009-03-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
EA018724B1 (ru) 2006-08-07 2013-10-30 Айронвуд Фармасьютикалз, Инк. Соединения индола
KR101485199B1 (ko) 2006-09-19 2015-01-22 다이이찌 산쿄 가부시키가이샤 피라졸로피리미딘 유도체
US7858645B2 (en) * 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
AP2010005345A0 (en) * 2008-02-29 2010-08-31 Pfizer Indazole derivatives.
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
KR101663335B1 (ko) 2008-12-22 2016-10-06 메르크 파텐트 게엠베하 6-（1-메틸-1ｈ-피라졸-4-일）-2-｛3-［5-（2-모르폴린-4-일-에톡시）-피리미딘-2-일］-벤질｝-2ｈ-피리다진-3-온디히드로겐포스페이트의 신규한 다형체 및 이의 제조 방법
MX2011008677A (es) 2009-02-25 2011-09-08 Daiichi Sankyo Co Ltd Derivados de pirazolopirimidina triciclicos.
TW201213333A (en) 2010-08-23 2012-04-01 Daiichi Sankyo Co Ltd Crystal forms of tricyclic pyrazolopyrimidine derivative
JPWO2012026433A1 (ja) 2010-08-23 2013-10-28 第一三共株式会社 三環性ピラゾロピリミジン誘導体のフリー体結晶
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
CN104736202B (zh) 2012-08-22 2021-09-07 康奈尔大学 用于抑制肌成束蛋白的方法
CA2939082C (fr) 2014-02-13 2022-06-07 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
JP6691869B2 (ja) * 2014-02-20 2020-05-13 コーネル ユニヴァーシティー ファシンを阻害するための化合物及び方法
WO2016007731A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1
WO2016007727A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
WO2016007722A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
CR20180152A (es) 2015-08-12 2018-08-09 Incyte Corp Sales de un inhibidor de lsd1
CA3010615C (fr) * 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Modulateurs de mastocytes et leurs utilisations
WO2017121693A1 (fr) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Thiazolamides et thiadiazolamides substitués et leur utilisation
MX2018012901A (es) 2016-04-22 2019-06-06 Incyte Corp Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
EP3564214A1 (fr) 2018-05-04 2019-11-06 Universita' Degli Studi G. D Annunzio Chieti - Pescara Dérivés d'indazole en tant que modulateurs du système de cannabinoïdes
WO2020047198A1 (fr) 2018-08-31 2020-03-05 Incyte Corporation Sels d'un inhibiteur de lsd1 et leurs procédés de préparation
US11787791B2 (en) 2018-09-28 2023-10-17 Acucela Inc. Inhibitors of VAP-1
KR102241064B1 (ko) * 2019-07-30 2021-04-16 부산대학교 산학협력단 신규한 인돌 유도체 및 이를 포함하는 염증성 질환 예방 또는 치료용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHENG C.Y. ET AL.: "Indazole carboxylic acids in male contraception", CONTRACEPTION, vol. 65, no. 4, 2002, pages 265 - 268, XP003001053 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors

Also Published As

Publication number Publication date
WO2006015263A2 (fr) 2006-02-09
TW200612918A (en) 2006-05-01

Similar Documents

Publication Publication Date Title
WO2006015263A3 (fr) Analogues de lonidamine
EP1835929B8 (fr) Procédés et traitements combinés anti-kir
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
AU2003213144A1 (en) Alkylating agent combinations in the treatment of cancer
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
WO2004030615A8 (fr) Compositions et procedes de diagnostic et de traitement de tumeur
EP1571968A3 (fr) Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
WO2004016225A8 (fr) Compositions et methodes de diagnostic et de traitement des tumeurs
WO2004045516A9 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
AU2003302892A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2003237367A1 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
EP1587837A3 (fr) Diagnostic et traitement du cancer de la prostate
EP1572091A3 (fr) Compositions et methodes de diagnostic et de traitement de tumeurs
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
WO2006113483A3 (fr) Methodes et compositions pour le traitement ou la prevention du cancer
WO2004060270A8 (fr) Compositions et methodes pour diagnostiquer et traiter des tumeurs
IL180138A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinol (pi) 3-kinase inhibitors and their use in the treatment of cancer
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2003057160A8 (fr) Compositions et methodes de diagnostic et de traitement d'une tumeur
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
WO2006015191A3 (fr) Analogues de lonidamine multicycliques
WO2005003154A8 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
AP2005003362A0 (en) Formulation and methods for the treatment of thrombocythemia.
HK1105288A1 (en) Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11346632

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 11346632

Country of ref document: US

122 Ep: pct application non-entry in european phase